TABLE 1.
Baseline characteristics of transplant recipients enrolled in the studya
| Variableb | Value for transplant recipientsc |
P value | |
|---|---|---|---|
| With IPA (n = 91) | Without IPA (n = 348) | ||
| Age at transplantation, no. (%) | |||
| ≤20 yrs | 13 (14.3) | 69 (19.8) | 0.264 |
| 21–40 yrs | 23 (25.3) | 101 (29.0) | |
| >40 yrs | 55 (60.4) | 178 (51.2) | |
| Gender, no. (%) | |||
| Female | 38 (41.8) | 150 (43.1) | 0.859 |
| Male | 53 (58.2) | 198 (56.9) | |
| Underlying disease, no. (%) | |||
| Acute leukemia | 49 (53.8) | 179 (51.5) | 0.115 |
| Lymphoproliferative diseases | 14 (15.4) | 69 (19.8) | |
| Myelodysplastic/myeloproliferative diseases | 13 (14.3) | 30 (8.6) | |
| Chronic myeloproliferative diseases | 7 (7.7) | 20 (5.7) | |
| Aplastic anemia | 6 (6.6) | 17 (4.9) | |
| Other | 2 (2.2) | 33 (9.5) | |
| Transplantation type, no. (%) | |||
| Matched, related | 34 (37.4) | 169 (48.6) | 0.037 |
| Matched, unrelated | 33 (36.3) | 81 (23.3) | |
| Mismatched, related | 0 (0.0) | 7 (2.0) | |
| Mismatched, unrelated | 24 (26.4) | 91 (26.2) | |
| Graft source, no. (%) | |||
| Peripheral blood | 80 (87.9) | 287 (82.5) | 0.506 |
| Bone marrow | 10 (11.0) | 53 (15.2) | |
| Cord blood | 1 (1.1) | 8 (2.3) | |
| Disease stage, no. (%) | |||
| First complete remission | 49 (53.8) | 188 (54.0) | 0.800 |
| Second or subsequent remission, or relapse | 13 (14.3) | 59 (17.0) | |
| Active disease | 29 (31.9) | 101 (29.0) | |
| Conditioning regimen, no. (%) | |||
| RIC | 68 (74.7) | 228 (65.5) | 0.091 |
| Myeloablative | 23 (25.3) | 120 (34.5) | |
| CMV serostatus of donor and recipient, no. (%) | |||
| D−/R+ or D+/R+ | 80 (87.9) | 313 (89.9) | 0.504 |
| D−/R− or D+/R− | 11 (12.1) | 35 (10.1) | |
| Duration of neutropenia,d mean days (range) | 13.1 (8–39) | 13.5 (5–35) | 0.460 |
| Acute GVHD, no. (%) | |||
| No GVHD or grades I–II | 63 (69.2) | 302 (86.8) | 0.0002 |
| Grades III–IV | 28 (30.8) | 46 (13.2) | |
| Antifungal prophylaxis, no. (%)e | |||
| Fluconazole | 42 (46.2) | 117 (33.6) | 0.002 |
| Posaconazole | 26 (28.6) | 107 (30.8) | |
| Other | 9 (9.9) | 14 (4.0) | |
| None or unknown | 14 (15.4) | 110 (31.6) | |
Twenty-one patients with “possible” IPA were excluded. Lymphoproliferative diseases included cases of chronic lymphocytic leukemia, multiple myeloma, and B- and T-cell lymphomas. Chronic myeloproliferative diseases included cases of chronic myelogenous leukemia and primary myelofibrosis. Other diseases included cases of idiopathic medullar aplasia, lymphohistiocytosis, hemoglobinopathies, and paroxysmal nocturnal hemoglobinuria.
RIC, reduced intensity conditioning; CMV, cytomegalovirus; D, donor; R, recipient; GVHD, graft-versus-host-disease.
The number of transplant recipients (percentage) with the characteristic are shown.
Neutropenia was defined as ≤0.5 × 109 cells/liter.
Other antifungals used in prophylaxis included voriconazole, liposomal amphotericin B, itraconazole and caspofungin. P values were calculated by Fisher’s exact probability t test or Student’s t test for continuous variables.